Petros Grivas

No bio available.

Financial relationships

  • Type of financial relationship:
    Professional Services
    Ineligible company:
    BostonGene
    Date added:
    06/15/2024
    Date updated:
    06/15/2024
  • Type of financial relationship:
    Professional Services
    Ineligible company:
    Fresenius Kabi
    Date added:
    06/15/2024
    Date updated:
    06/15/2024
  • Type of financial relationship:
    Professional Services
    Ineligible company:
    Lucence Health
    Date added:
    06/15/2024
    Date updated:
    06/15/2024
  • Type of financial relationship:
    Professional Services
    Ineligible company:
    PureTech
    Date added:
    06/15/2024
    Date updated:
    06/15/2024
  • Type of financial relationship:
    Professional Services
    Ineligible company:
    G1 Therapeutics
    Date added:
    06/15/2024
    Date updated:
    06/15/2024
  • Type of financial relationship:
    Professional Services
    Ineligible company:
    Aadi Biosciences
    Date added:
    06/15/2024
    Date updated:
    06/15/2024
  • Type of financial relationship:
    Professional Services
    Ineligible company:
    CG Oncology
    Date added:
    06/15/2024
    Date updated:
    06/15/2024
  • Type of financial relationship:
    Professional Services
    Ineligible company:
    Strata Oncology
    Date added:
    06/15/2024
    Date updated:
    06/15/2024
  • Type of financial relationship:
    Professional Services
    Ineligible company:
    Immunity Bio
    Date added:
    06/15/2024
    Date updated:
    06/15/2024
  • Type of financial relationship:
    Professional Services
    Ineligible company:
    Asieris Pharmaceuticals
    Date added:
    06/15/2024
    Date updated:
    06/15/2024

Pages

Return to Optimizing Immuno-Oncology: Innovations in Immune Checkpoint Inhibitor Delivery